RT Journal Article
SR Electronic
T1 No Compensation in VEGF Expression Follows Antisense Suppression of BCL-2 Activity
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 937
OP 940
VO 26
IS 6
A1 RUBENSTEIN, MARVIN
A1 HOLLOWELL, COURTNEY M.P.
A1 GUINAN, PATRICK
YR 2012
UL http://iv.iiarjournals.org/content/26/6/937.abstract
AB Antisense oligonucleotides (oligos) have been employed against prostate cancer models targeting growth-regulatory proteins, and at least one oligo (against bcl-2) has reached clinical trial. We previously found that, in LNCaP cells, mono- and bispecific oligos, which comparably suppressed the expression of bcl-2, compensated with suppression of caspase-3 (apoptosis promoter) activity, and enhanced the expression of the androgen receptor (AR) and its p300 and IL-6 co-activators. In addition, prostate-specific membrane antigen (PSMA) and (possibly its regulator) interferon (IFN) were elevated. A total of 14 proteins distributed between regulators of apoptosis, androgen regulation, differentiation antigens and autocrine-mediated growth have previously been examined. We extend these findings to include vascular endothelial growth factor (VEGF), a promoter of angiogenesis, which is not significantly altered through compensation, and therefore would not need additional regulation for suppressive bcl-2 therapy to be effective (like caspase-3).